Biotech / Medical
Provectus Pharmaceuticals Inc.
An SI Board Since April 2006
Posts SubjectMarks Bans Symbol
13074 110 0 PVCT
Emcee:  Jack Russell Type:  Moderated

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.

Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes:

PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.

Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.

PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at

Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read detailed Research Reports


Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT,, a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application.

The "Provectus IR" App is available for download from the App Store at and from the Google Play Store at The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.


Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"


*PV-10 link to video and visual references:

PV-10 Trial Participants Telling Their Own Stories in the News

May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.

2008, Charles Dawson, PV10 patient, Australia; Professor John Thompson, Sydney Melanoma Unit

Video can be viewed here

December 16, 2010
Madja Rauh recently traveled to Bethlehem with her daughter Ursa Rauh from Ljubljana, the capital of Slovenia in Europe, to receive a promising, experimental treatment for metastatic melanoma with internationally recognized melanoma investigator Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology, St. Luke's Hospital & Health Network,Bethlehem, PA

Video can be viewed here.
Madja Rauh, PV10 patient, has a Facebook page as of 1/ 2015
Madja Rauh, PV-10 patient, has a Facebook page as of January 2015

May/June 2014

“Very Impressive Data” for Rose Bengal 10% in Intralesional Melanoma

Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, says a phase 2 trial of Rose Bengal 10% as a chemical ablative agent injected directly into melanoma tumors yielded “very impressive data.” Even “bystander” lesions that were not injected showed good partial and complete responses, confirming the agent’s systemic value. Because of low toxicity, the treatment could be useful not only in combination with other therapies but as monotherapy for patients who aren’t good candidates for more toxic systemic treatments. American Society of Clinical Oncology, May/June 2014

Video can be viewed here.


PV-10 Audio References:

May 9, 2014 Dr. Sanjiv Agarwala Discusses PV-10 on Daybreak USA

On a recent airing of USA Radio National's Daybreak USA, host Jay Young interviewed Dr. Sanjiv S. Agarwala of St. Luke's Cancer Center in recognition of melanoma awareness month. Dr. Agarwala discusses melanoma risks and treatment as well as exciting results from his clinical work with treating advanced melanoma with PV-10.

With the permission of USA Radio National, an audio track containing the interview that aired on Daybreak USA is available at:


PVCT insiders transactions:


Contact Info

Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302

Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075

Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700

Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031

Company Website

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
13074Hey! 1,000,000+ shares. Up 20% to over .50. Why no action on this thread? Bob Miller-April 28
13073Hey Willie J whats your beef...Jack Russell-February 27
13072The wallstreet.orgJack Russell-February 4
13071 Provectus Biopharma (PVCT) Confirms Dosing in PV-10 Phase 3 streetinsider.comJack Russell-January 12
13070I am glad it worked out for him... And the ridiculous part of your statement isJack Russell-January 7
13069Jack.... no doubt you disagree, but the facts are the facts...and frail old JimmNTTG-January 5
13068I would disagree... Good for Mr Carter I am happy for him... The Side affects ofJack Russell-12/10/2015
13067Lets see...they successfully completed a PIII, got FDA approval, and are now beiNTTG-12/7/2015
13066LOL TVEC does little beyond the horrible side affects....Jack Russell-12/3/2015
13065I have no issue with T Vec data or the MOA. It will be interesting to watch theiNTTG-12/3/2015
13064Yawn, more nondescript mousey dataNTTG-11/9/2015
13063Provectus Biopharmaceuticals Reports Immune Mechanism of Action Data for PV-10 Jack Russell-11/6/2015
13062T-Vec and its side affects are downright Horrible with no appreciable good qualiJack Russell-10/30/2015
13061T Vec approved, PVCT still struggling to get a PIII for indolent melanoma done. NTTG-10/28/2015
13060Yawn, a double dip review article, read the footnoteNTTG-10/5/2015
13059Quality institutions, or just high risk hedge funds...NTTG-10/5/2015
13058 Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 TuJack Russell-9/30/2015
13056Hey SG, Congrats on retirement, sorry to hear of your personal illness, best NTTG-8/21/2015
13055Hi NTTG, Haven't been back to SI for a while and saw your old post to me. NSG-8/19/2015
13054No joy over another patent? strangeNTTG-8/18/2015
13053It is obvious from the PR Jack, SINO is no longer interested in signing endless NTTG-7/27/2015
13052Is this just you being less than truthful again or do you have some sort of insiJack Russell-7/18/2015
13051SINO is walking away, nice progressNTTG-7/17/2015
13050ZERO up front cash, classicNTTG-7/2/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.